首页> 美国卫生研究院文献>Clinical and Translational Gastroenterology >Probiotic/Synbiotic Treatment and Postoperative Complications in Colorectal Cancer Patients: Systematic Review and Meta-analysis of Randomized Controlled Trials
【2h】

Probiotic/Synbiotic Treatment and Postoperative Complications in Colorectal Cancer Patients: Systematic Review and Meta-analysis of Randomized Controlled Trials

机译:益生菌/同步治疗和结肠直肠癌患者的术后并发症:随机对照试验的系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Colorectal cancer (CRC) is a leading cause of morbidity and mortality. Post-CRC resection complications and lower quality of life (QoL) are associated with a lower long-term survival. Perioperative administration of probiotics/synbiotics might lower prevalence of side effects and improve QoL and survival among CRC patients. Medline, Web of Science, Cochrane database, Embase, and clinical trials registries were searched in January 2020. Altogether, 16 randomized placebo-controlled probiotic/synbiotic clinical trials that included patients undergoing CRC surgery and investigated postoperative complications and QoL side effects were found. Meta-analyses using random-effects model were performed on data from 11 studies to calculate the effects of probiotics/synbiotics on common CRC resection postoperative side effects and complications. Perioperative probiotics/synbiotics administration was associated with lower infection incidence (odds ratio [OR] = 0.34, P < 0.001), lower diarrheal incidence (OR = 0.38, P < 0.001), faster return to normal gut function (mean difference [MD] −0.66 days, P < 0.001), shorter postoperative antibiotics use (MD −0.64 days, P < 0.001), lower incidence of septicemia (OR = 0.31, P < 0.001), and shorter length of hospital stay (MD −0.41 days, P = 0.110). The results support the hypothesis that short-term perioperative administration of probiotics/synbiotics, which are easy to administer, have few side-effects, and are low cost compared with alternatives, might help to alleviate gastrointestinal symptoms and postoperative complications among CRC patients.
机译:结肠直肠癌(CRC)是发病率和死亡率的主要原因。后CRC切除并发症和较低的生活质量(QOL)与较低的长期存活相关。围手术期益生菌/ Synbiotics施用可能降低副作用的患病率,提高CRC患者的QoL和生存率。 Medline,科学数据库,EMBASE和EMBASE和临床试验登记处被搜查于2020年20日。在含有接受CRC手术和调查的术后并发症和QOL副作用的患者中,16种随机安慰剂对照益生菌/同步临床试验中得到了研究。使用随机效应模型的META分析进行了来自11项研究的数据进行,以计算益生菌/ Synbiotics对常见CRC切除术后副作用和并发症的影响。围手术期益生菌/ Synbiotics施用与较低的感染发生率(差异= 0.34,p <0.001),较低的腹泻发生率(或= 0.38,p <0.001)相关,恢复正常肠功能(平均差异[MD] -0.66天,p <0.001),术后术后较短(MD -0.64天,P <0.001),败血症发病率降低(或= 0.31,P <0.001),以及较短的住院住宿时间(MD -0.41天, p = 0.110)。结果支持假设易于施用的益生菌/ Synbiotics的短期围手术期施用,易于施用,并且与替代方案相比,低成本可能有助于缓解CRC患者的胃肠道症状和术后并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号